Kenneth Shropshire
Known title: DirectorCIK: 0001358892
Associated companies
Transaction History
| MC | ▲ Buy | Grant | 20 | — | 9/17/2026 | View on chart |
| MC | ▲ Buy | Grant | 19 | — | 9/17/2026 | View on chart |
| MC | ▲ Buy | Grant | 2 | — | 9/17/2026 | View on chart |
| MC | ▼ Sell | Open Market | 1,881 | $130K | 8/27/2026 | View on chart |
| MC | ▲ Buy | Grant | 1,700 | — | 7/1/2026 | View on chart |
| MC | ▲ Buy | Grant | 200 | — | 7/1/2026 | View on chart |
| MC | ▲ Buy | Grant | 1 | — | 6/18/2026 | View on chart |
| MC | ▲ Buy | Grant | 18 | — | 6/18/2026 | View on chart |
| MC | ▲ Buy | Grant | 21 | — | 6/18/2026 | View on chart |
| MC | ▲ Buy | Grant | 25 | — | 3/26/2026 | View on chart |
| MC | ▲ Buy | Grant | 21 | — | 3/26/2026 | View on chart |
| MC | ▲ Buy | Grant | 1 | — | 3/26/2026 | View on chart |
| MC | ▲ Buy | Grant | 21 | — | 12/4/2025 | View on chart |
| MC | ▲ Buy | Grant | 17 | — | 12/4/2025 | View on chart |
| MC | ▲ Buy | Grant | 2 | — | 12/4/2025 | View on chart |
| MC | ▲ Buy | Grant | 2 | — | 9/18/2025 | View on chart |
| MC | ▲ Buy | Grant | 15 | — | 9/18/2025 | View on chart |
| MC | ▲ Buy | Grant | 18 | — | 9/18/2025 | View on chart |
| MC | ▼ Sell | Open Market | 2,615 | $190K | 8/22/2025 | View on chart |
| MC | ▲ Buy | Grant | 1,761 | — | 7/1/2025 | View on chart |
| MC | ▲ Buy | Grant | 208 | — | 7/1/2025 | View on chart |
| MC | ▲ Buy | Grant | 30 | — | 6/20/2025 | View on chart |
| MC | ▲ Buy | Grant | 24 | — | 6/20/2025 | View on chart |
| MC | ▲ Buy | Grant | 1 | — | 6/20/2025 | View on chart |
| MC | ▲ Buy | Grant | 28 | — | 3/27/2025 | View on chart |
| MC | ▲ Buy | Grant | 22 | — | 3/27/2025 | View on chart |
| MC | ▲ Buy | Grant | 1 | — | 3/27/2025 | View on chart |
| MC | ▼ Sell | Open Market | 2,551 | $184K | 2/21/2025 | View on chart |
| MC | ▲ Buy | Grant | 20 | — | 12/2/2024 | View on chart |
| MC | ▲ Buy | Grant | 16 | — | 12/2/2024 | View on chart |
| MC | ▲ Buy | Grant | 1 | — | 12/2/2024 | View on chart |
| MC | ▲ Buy | Grant | 22 | — | 9/26/2024 | View on chart |
| MC | ▲ Buy | Grant | 18 | — | 9/26/2024 | View on chart |
| MC | ▲ Buy | Grant | 2 | — | 9/26/2024 | View on chart |
| MC | ▼ Sell | Open Market | 495 | $34K | 7/31/2024 | View on chart |
| MC | ▲ Buy | Grant | 2,030 | — | 7/1/2024 | View on chart |
| MC | ▲ Buy | Grant | 239 | — | 7/1/2024 | View on chart |
| MC | ▲ Buy | Grant | 4 | — | 6/20/2024 | View on chart |
| MC | ▲ Buy | Grant | 28 | — | 6/20/2024 | View on chart |
| MC | ▲ Buy | Grant | 23 | — | 6/20/2024 | View on chart |
| MC | ▲ Buy | Grant | 1 | — | 6/20/2024 | View on chart |
| MC | ▲ Buy | Grant | 2 | — | 3/28/2024 | View on chart |
| MC | ▲ Buy | Grant | 26 | — | 3/28/2024 | View on chart |
| MC | ▲ Buy | Grant | 22 | — | 3/28/2024 | View on chart |
| MC | ▲ Buy | Grant | 3 | — | 3/28/2024 | View on chart |
| MC | ▲ Buy | Grant | 21 | — | 12/22/2023 | View on chart |
| MC | ▲ Buy | Grant | 3 | — | 12/22/2023 | View on chart |
| MC | ▲ Buy | Grant | 26 | — | 12/22/2023 | View on chart |
| MC | ▲ Buy | Grant | 2 | — | 12/22/2023 | View on chart |
| MC | ▲ Buy | Grant | 27 | — | 9/22/2023 | View on chart |
| MC | ▲ Buy | Grant | 4 | — | 9/22/2023 | View on chart |
| MC | ▲ Buy | Grant | 33 | — | 9/22/2023 | View on chart |
| MC | ▲ Buy | Grant | 4 | — | 9/22/2023 | View on chart |
| MC | ▼ Sell | Open Market | 1,417 | $68K | 8/10/2023 | View on chart |
| MC | ▲ Buy | Grant | 2,446 | — | 7/3/2023 | View on chart |
| MC | ▲ Buy | Grant | 289 | — | 7/3/2023 | View on chart |
| MC | ▲ Buy | Grant | 21 | — | 6/23/2023 | View on chart |
| MC | ▲ Buy | Grant | 28 | — | 6/23/2023 | View on chart |
| MC | ▲ Buy | Grant | 1 | — | 6/23/2023 | View on chart |
| MC | ▲ Buy | Grant | 4 | — | 6/23/2023 | View on chart |
| MC | ▲ Buy | Grant | 0 | — | 6/23/2023 | View on chart |
| MC | ▲ Buy | Grant | 309 | — | 4/3/2023 | View on chart |
| MC | ▲ Buy | Grant | 13 | — | 4/3/2023 | View on chart |
| MC | ▲ Buy | Grant | 23 | — | 3/28/2023 | View on chart |
| MC | ▲ Buy | Grant | 31 | — | 3/28/2023 | View on chart |
| MC | ▲ Buy | Grant | 2 | — | 3/28/2023 | View on chart |
| MC | ▲ Buy | Grant | 19 | — | 12/2/2022 | View on chart |
| MC | ▲ Buy | Grant | 26 | — | 12/2/2022 | View on chart |
| MC | ▲ Buy | Grant | 3 | — | 12/2/2022 | View on chart |
| MC | ▲ Buy | Grant | 19 | — | 8/23/2022 | View on chart |
| MC | ▲ Buy | Grant | 25 | — | 8/23/2022 | View on chart |
| MC | ▲ Buy | Grant | 4 | — | 8/23/2022 | View on chart |
| MC | ▲ Buy | Grant | 1,885 | — | 7/1/2022 | View on chart |
| MC | ▲ Buy | Grant | 289 | — | 7/1/2022 | View on chart |
| MC | ▲ Buy | Grant | 43 | — | 6/21/2022 | View on chart |
| MC | ▲ Buy | Grant | 12 | — | 6/21/2022 | View on chart |
| MC | ▲ Buy | Grant | 21 | — | 6/8/2022 | View on chart |
| MC | ▲ Buy | Grant | 18 | — | 6/8/2022 | View on chart |
| MC | ▲ Buy | Grant | 1 | — | 6/8/2022 | View on chart |
| MC | ▲ Buy | Grant | 1 | — | 3/28/2022 | View on chart |
| MC | ▲ Buy | Grant | 17 | — | 3/28/2022 | View on chart |
| MC | ▲ Buy | Grant | 19 | — | 3/28/2022 | View on chart |
| MC | ▲ Buy | Grant | 67 | — | 11/19/2021 | View on chart |
| MC | ▲ Buy | Grant | 58 | — | 11/19/2021 | View on chart |
| MC | ▲ Buy | Grant | 6 | — | 11/19/2021 | View on chart |
| MC | ▼ Sell | Gift | 156 | $0 | 10/29/2021 | View on chart |
| MC | ▼ Sell | Open Market | 2,142 | $154K | 10/28/2021 | View on chart |
| MC | ▲ Buy | Grant | 14 | — | 9/17/2021 | View on chart |
| MC | ▲ Buy | Grant | 12 | — | 9/17/2021 | View on chart |
| MC | ▲ Buy | Grant | 2 | — | 9/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Moelis faces mixed analyst actions with lowered price targets
Morgan Stanley maintained its Overweight rating on Moelis but cut its price target to $77. Meanwhile, UBS upgraded the stock to Neutral while lowering its target to $59. These moves reflect a cautious outlook from major banks, with the average analyst target now sitting at $68.70.
Moelis faces mixed analyst actions with lowered price targets. Morgan Stanley maintained its Overweight rating on Moelis but cut its price target to $77. Meanwhile, UBS upgraded the stock to Neutral while lowering its target to $59. These moves reflect a cautious outlook from major banks, with the average analyst target now sitting at $68.70.